Wobenzym (chymotrypsin,trypsin) pills

Instructions for Wobenzym (chymotrypsin,trypsin)

English product name
Wobenzym®

Release Form Wobenzym
Intestinal-soluble, shell-coated tablets

Description Wobenzym

The tablets are intestinal-soluble, covered with a shell from red-orange to red, round, double-convex, with a smooth surface, with a characteristic smell.

1 tab.
pancreatin 300 WIP* (100 mg)
papain 90 FIP (18 mg)
rutoside trihydrate 50 mg
bromelain 225 FIP (45 mg)
trypsin 360 FIP (12 mg)
lipase 34 FIP (10 mg)
amylase 50 FIP (10 mg)
chymotrypsin 300 FIP (0.75 mg)
* protease activity FIP units.

Auxiliary substances Wobenzym: lactose monohydrate - 149 mg, pregelatinized starch - 31.3 mg, magnesium stearate - 6 mg, stearic acid - 6 mg, silicon dioxide colloidal anhydrous - 3 mg, talc - 1.5 mg.

The shell comprises a film shell of 11.9 mg (copolymer of methacrylic acid-methylmethacrylate (1:1)-11.9 mg, sodium lauryl sulfate-0.04 mg), talc of 4.23 mg, macrogol 6000-0.67 mg, triethyl citrate of 1.2 mg, stearic acid of 6 mg, and a coloured coating of 12.8 mg (hypromellose 3.2 mg, hydroxypropyl cellulose 3.83 mg, microcrystalline cellulose 1.6 mg, and glycemic cellulose Rol - 0.64 mg, talc - 1.92 mg, titanium dioxide - 0.38 mg, powder dye 4R (E124) - 0.38 mg, yellow-orange dye S (E110) - 0.83 mg).

20 pcs. - PVC/PE/PVC/Aluminium blisters (2) - cardboard packs.
20 pcs. - PVC/PE/PVC/Aluminium blister packs (5) - cardboard packs.
20 pcs. - PVC/PE/PVC/Aluminium blisters (10) - cardboard packs.
800 units - high-density polyethylene bottles - cardboard packs.

ATC codes
L03AX Other immunostimulators

Clinical-pharmacological groups / Group affiliation
Preparation having an anti-inflammatory and immuno-modulating effect

Active substance Wobenzym

1. pancreatin
2. amylase
3. papain
4. lipase
5. bromelain
6. trypsin
7. chymotrypsin
8. rutoside trihydrate

Pharmaco-therapeutic group Wobenzym

Anti-inflammatory, immuno-modulating agent

Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.

Best before date Wobenzym
The shelf life is two years. Do not apply after expiry date.

Pharmacological effect Wobenzym

Wobenzym is a combination of natural enzymes of plant and animal origin. By entering the body, enzymes are absorbed from the small intestine by resorption of intact molecules and, by binding to the blood transport proteins, enter the bloodstream. In the future, the enzymes that migrate along the vascular channel and accumulate in the pathological process area have an immunomodulatory, anti-inflammatory, fibrinolytic, anti-edema, anti-agregant and secondary analgesic effect.

The preparation has a positive effect on the course of the inflammatory process, restricts the pathological manifestations of autoimmune and immunocomplex processes, and positively affects the indicators of immunological reactivity of the body. It stimulates and regulates the functional activity of macrophage monocytes and natural killer cells, stimulates anti-tumor immunity, cytotoxic T lymphocytes and phagocytic activity of cells.

The drug Wobenzym reduces the number of circulating immune complexes and removes membrane deposits of immune complexes from the tissues.

Wobenzym reduces infiltration by plasma cells. It increases the elimination of protein detritus and fibrin deposits in the inflammation zone, accelerates the lysis of toxic metabolism products and necrotizing tissues.

Normalizes penetrability of vascular walls, promotes faster absorption of hematomas and edema.

The Wobenzym regulates mechanisms of non-specific protection (interferon production), thereby exhibiting antiviral and antimicrobial effects.

Testimony Wobenzym

• As part of the complex therapy of the following diseases:
• Angiology
• thrombophlebitis, including acute thrombophlebitis of superficial veins;
• treatment of postthrombophlebitic disease;
• treatment of endarteritis and obliterating atherosclerosis of the arteries of the lower extremities;
• Prevention of relapsing phlebitis;
• lymphatic edema.
• Urology
• cystitis, cystopielitis;
• prostatite;
• sexually transmitted infections.
• Gynecology
• chronic genital infections, adnexitis;
• to reduce the frequency and severity of side effects of hormone replacement therapy in gynecology;
• mastopathy;
• gestoses.
• Cardiology
• voltage angina;
• The subacute stage of myocardial infarction (to improve the rheological properties of the blood).
• Pulmonology:
• sinusitis;
• bronchitis, pneumonia.
• Gastroenterology
• pancreatitis;
• hepatitis.
• Nephrology
• Pyelonephrite;
• glomerulonephritis.
• Endocrinology
• diabetic angiopathy, diabetic retinopathy;
• autoimmune thyroid.
• Rheumatology
• rheumatoid arthritis;
• reactive arthritis;
• Bechterev's disease.
• Dermatology
• atopic dermatitis;
• acne rash.
• Neurology
• multiple sclerosis.
• Ophthalmology:
• uveitis, iridocyclite;
• haemophthalm;
• diabetic retinopathy;
• application in ophthalmic surgery.
• Pediatrics
• atopic dermatitis;
• Respiratory tract infection and inflammation (upper and lower respiratory tract inflammation, pneumonia);
• juvenile rheumatoid arthritis;
• Prevention and treatment of postoperative complications (suppuration and poor wound healing, formation of adhesions, local swelling).
• Surgery
• Prevention and treatment of post-operative complications (inflammatory processes, thrombosis, edema), sleeping sickness, post-traumatic and lymphatic edema;
• plastic and reconstructive surgery.
• Traumatology
• injuries, fractures;
• distortion, damage to the communications apparatus;
• bruises;
• chronic post-traumatic processes;
• inflammation of the soft tissues;
• burns;
• injuries in sports medicine.
• Prevention
• microcirculation disorders, post-stress disorders, and failure of adaptation mechanisms;
• side effects of hormone replacement therapy, hormonal contraception;
• Surgical interventions to prevent infectious complications and sleeping sickness.
• It is recommended to prevent infectious complications and improve the quality of life during chemo- or radiotherapy; viral
• infections; and their complications.

• Nosology Wobenzym (ICD codes)
• A64
• Unspecified sexually transmitted diseases
• B15
• Acute hepatitis A
• B16
• Acute hepatitis B
• B17.1
• Acute hepatitis C
• B18.0
• Chronic viral hepatitis B with delta agent
• B18.1
• Chronic viral hepatitis B without delta agent
• B18.2
• Chronic viral hepatitis C
• B34.9
• Viral infection unspecified
• E06.3
• Autoimmune thyroiditis
• G35
• Multiple sclerosis
• H20.0
• Acute and subacute iridocyclite (anterior uveitis)
• H20.1
• Chronic iridocyclite
• H36.0
• Diabetic retinopathy
• H44.8
• Other diseases of the eyeball (including haemophthalm)
• I20
• Angina [pectoral toad]
• I21
• Acute myocardial infarction
• I70
• Atherosclerosis
• I73.1
• Clotting Thrombangitis [Berger's disease]
• I73.8
• Other Specified Peripheral Vascular Diseases
• I79.2
• Peripheral angiopathy for diseases classified in other headings (including diabetic angiopathy)
• I80
• Phlebitis and thrombophlebitis
• I87.0
• Post-thrombotic syndrome
• I89.0
• Lymphoedema not classified in other categories
• J01
• Acute sinusitis
• J06.9
• Acute upper respiratory tract infection unspecified
• J15
• Bacterial pneumonia not classified elsewhere
• J20
• Acute bronchitis
• J32
• Chronic sinusitis
• J42
• Chronic bronchitis unspecified
• K66.0
• Abdominal adhesions
• K73
• Chronic hepatitis not classified elsewhere
• K86.1
• Other chronic pancreatitis
• L20.8
• Other atopic dermatitis (neurodermatitis, eczema)
• L70
• Ugri
• M02
• Reactive arthropathy
• M05
• Seropositive rheumatoid arthritis
• M08
• Juvenile [juvenile] arthritis
• M45
• Ankylosing spondylitis
• M65
• Synovitis and tenosinovites
• M70
• Soft tissue diseases related to load, overload and pressure
• M71
• Other bursopathy
• M79.8
• Other specified soft tissue lesions
• N00
• Acute jade syndrome (acute glomerulonephritis)
• N03
• Chronic nephritic syndrome
• N10
• Acute tubuloinsterstitial nephritis (acute pielonephritis)
• N11
• Chronic tubulointerstitial nephritis (chronic pyelonephritis)
• N30
• Cystitis
• N34
• Urethritis and urethral syndrome
• N41
• Inflammatory prostate diseases
• N60
• Benign breast dysplasia (including fibrous cystic mastopathy)
• N70
• Salpingitis and oophorite
• N72
• Inflammatory disease of the cervix (incl. cervicite, endocervicite, exocervicite)
• N99.4
• Post-operative adhesions in the small pelvis
• O13
• Pregnancy-induced hypertension
• O15
• Eclampsia
• T14.0
• Superficial injury of an unspecified area of the body (including abrasion, bruising, bruising, hematoma, bite of a non-venomous insect)
• T14.2
• Fracture in unspecified body region
• T14.3
• Dislocation, stretching and overtension of the capsule-bonding apparatus of the unspecified body region joint
• T14.9
• Injury unspecified
• T30
• Thermal and chemical burns of unspecified location
• T79.3
• Post-traumatic wound infection not classified elsewhere
• T88.8
• Other specified complications of surgical and therapeutic interventions not classified elsewhere
• Y42.4
• Oral contraceptives
• Y42.5
• Other estrogens and progestagens
• Y43.3
• Other anti-tumour drugs
• Y84.2
• Radiological procedure and radiotherapy
• Z29.8
• Other specific preventive measures
• Z51.8
• Other refined medical care

Method of use, course and dosage Wobenzym

The preparation is taken inside, at least 30 minutes before eating. The tablets should be swallowed without chewing, washed with water (200 ml).

Adults 
Depending on the activity and severity of the disease, the drug is taken in a dose of three to 10 tabs. three times in the course of the disease. In the first 3 days of taking the drug, the recommended dose is 3 tabb. 3 times/day.

In the case of moderate activity of the disease, the preparation is prescribed in a dose of 5-7 tabb. three times/day within two weeks. In the future, the dose of the drug should be reduced to 3-5 tabb. 3 times/day. Course - 2 weeks.

In case of high activity of the disease, the preparation is prescribed in a dose of 7-10 tabb. 3 times/day within 2-3 weeks. The dose should be reduced to 5 tabs. three times/day. Course - 2-3 months.

For chronic long-term diseases, Wobenzym can be used for indications ranging from 3 to 6 months or more.

In order to increase the effectiveness of antibiotics and prevent dysbacteriosis, the drug should be used throughout the course of antibiotic therapy in a dose of 5 tabi. 3 times / day. After stopping the course of antibiotic therapy to restore the microflora (biocenosis) of the intestine, Vobanzim should be prescribed three times a day for two weeks.

As a "cover" therapy during radiation and chemotherapy, the drug should be used in a dose of 5 taba. three times a day before the completion of radiation and chemotherapy to prevent infectious complications, improve tolerability of base therapy and improve the quality of life.

When the preparation is used with the prophylactic aim, the dose is 3 tabb. three times a day for 1.5 months with a repetition of the course of two - three times a year.

Children
Children aged 5-12 years are prescribed the drug in a dose of 1 tabb. for six kg of body weight per day. Children over 12 years of age are prescribed the drug in a scheme intended for adults. The dose and duration of treatment depends on the severity of the disease and is determined by the doctor.